Technical Analysis for HALO - Halozyme Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 18.0 2.80% 0.49
HALO closed up 2.8 percent on Thursday, July 19, 2018, on 77 percent of normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical HALO trend table...

Date Alert Name Type % Chg
Jul 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jul 19 Up 3 Days in a Row Strength 0.00%
Jul 17 Inside Day Range Contraction 3.63%
Jul 13 Bearish Engulfing Bearish 4.23%
Jul 13 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 4.23%
Jul 13 Inside Day Range Contraction 4.23%
Jul 12 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.51%
Jul 12 MACD Bullish Signal Line Cross Bullish 2.51%
Jul 11 Shooting Star Candlestick Bearish 4.65%
Jul 11 Doji - Bearish? Reversal 4.65%

Older signals for HALO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of solid tumors; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; Baxter Healthcare Corporation; ViroPharma Incorporated; and Intrexon Corporation for the development of three product candidates. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Is HALO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 21.48
52 Week Low 11.41
Average Volume 789,064
200-Day Moving Average 18.7849
50-Day Moving Average 18.2763
20-Day Moving Average 17.3965
10-Day Moving Average 17.377
Average True Range 0.5253
ADX 22.22
+DI 18.8905
-DI 16.4342
Chandelier Exit (Long, 3 ATRs ) 17.9841
Chandelier Exit (Short, 3 ATRs ) 18.0459
Upper Bollinger Band 18.2935
Lower Bollinger Band 16.4995
Percent B (%b) 0.84
BandWidth 10.312419
MACD Line -0.2369
MACD Signal Line -0.3498
MACD Histogram 0.1129
Fundamentals Value
Market Cap 2.41 Billion
Num Shares 134 Million
EPS -0.93
Price-to-Earnings (P/E) Ratio -19.35
Price-to-Sales 16.99
Price-to-Book 39.19
PEG Ratio -2.38
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.04
Resistance 3 (R3) 18.93 18.47 18.86
Resistance 2 (R2) 18.47 18.21 18.53 18.80
Resistance 1 (R1) 18.24 18.05 18.36 18.35 18.75
Pivot Point 17.78 17.78 17.84 17.84 17.78
Support 1 (S1) 17.55 17.52 17.67 17.66 17.25
Support 2 (S2) 17.09 17.36 17.15 17.20
Support 3 (S3) 16.86 17.09 17.14
Support 4 (S4) 16.97